The preliminary study of our experimental group found that bone marrow mesenchymal stem cells(BMSCs) can inhibit the immune response of CD8 + T cells in multiple myeloma through the PD-1/PD-L1 pathway, and this finding also provides a new idea for the treatment of myeloma [53]. This evidence concerns the gene CD8A and plasma cell myeloma.